{"nctId":"NCT01031680","briefTitle":"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension","startDateStruct":{"date":"2010-02"},"conditions":["Type 2 Diabetes Mellitus","Cardiovascular Disease","Hypertension","Inadequate Glycaemic Control"],"count":922,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus.\n* Cardiovascular disease\n* Hypertension\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes or diabetes insipidus\n* Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes\n* Any clinically significant illness, which would compromise the patient's safety and their participation in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease and hypertension, measured as the mean change in HbA1c from baseline to week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":null},{"groupId":"OG001","value":"0.08","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit","description":"To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease and hypertension at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Seated Systolic Blood Pressure (SBP)","description":"To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.96","spread":null},{"groupId":"OG001","value":"-0.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Percent Change in Body Weight","description":"To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":null},{"groupId":"OG001","value":"-0.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 24 (LOCF)","description":"To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.99","spread":null},{"groupId":"OG001","value":"-1.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²","description":"To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":460},"commonTop":["Hypoglycemia"]}}}